Finasteride linked to fewer heart attack complications
Analysis based on 8 articles · First reported Aug 26, 2026 · Last updated Aug 29, 2026
The study may modestly boost interest in finasteride's potential cardioprotective effects, but it is observational and not expected to change clinical practice or significantly affect drug sales. Pharmaceutical companies with finasteride products could see minor positive sentiment, while the broader market impact is limited.
A registry study from the University of Gothenburg, published in JAMA Network Open, found that men taking finasteride for benign prostatic hyperplasia at the time of a severe ST-elevation myocardial infarction (STEMI) treated with balloon angioplasty had a lower risk of serious complications. Among finasteride users, 20.8% experienced serious complications (cardiac arrest, severe arrhythmias, severely impaired left ventricular function, or death within 30 days) versus 24.3% in matched controls. The study used data from the SWEDEHEART registry and national registers. The researchers caution that the finding is observational and does not currently support using finasteride as a heart attack treatment. No significant association was seen with hormone therapy for prostate cancer.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard